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Abstract
Visceral leishmaniasis (VL) in patients receiving immunosuppressant drugs for autoimmune
disease has been on the rise. It is important—but difficult—to know when cure has been
achieved in these patients since the withdrawal of immunosuppressants during antileishma-
nia treatment is commonly required, and there is a risk of relapse when immunosuppression
is restored. The prevalence of asymptomatic infection among those immunosuppressed for
autoimmune disease is also uncertain. The present work describes how cytokine release
assays can be used to confirm the cure of VL, and to determine the prevalence of asymp-
tomatic infection, in such patients. After collection of blood from volunteers (n = 108), SLA-
stimulation of peripheral blood mononuclear cell cultures and of whole blood was found to
induce the production of different combinations of cytokines that served to confirm recovery
from VL, and asymptomatic Leishmania infection. Indeed, cure was confirmed in 14
patients, all of whom showed a specific Th1 immune response against Leishmania, and the
prevalence of asymptomatic infection was determined as 21.27%. Cytokine profiles could
be used to manage VL in patients with autoimmune disease, and to identify and better pro-
tect those with asymptomatic infection who are at risk of developing this disease.
Author summary
Cytokine release assays were used to confirm the cure of visceral leishmaniasis in patients
(from an area where Leishmania infantum is endemic) with autoimmune disease. They
were also used to determine the prevalence of asymptomatic Leishmania infantum infec-
tion in similar patients. Some 21.27% of those with no clinical history of leishmaniasis
were shown to have been contact with the parasite.
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Introduction
Leishmaniasis, caused by Leishmania infantum, is endemic throughout peninsular Spain and
the Balearic Islands [1]. The annual incidence of this disease is 0.45/100,000 people, although
during an outbreak in Fuenlabrada (southeast of the Madrid region) in 2009 it reached 21.54/
100,000 [2].
Immunosuppression is a major risk factor for the development of the disease; it can also
alter how it presents and the response to treatment [3]. The focus on this problem has mainly
been within the context of HIV, but treatment for autoimmune conditions with immunosup-
pressive drugs is becoming more common [4,5], leaving patients more vulnerable to leishman-
iasis. For example, the appearance of visceral leishmaniasis (VL) has been associated with the
use of different immunosuppressants administered in the treatment of rheumatism, including
methotrexate, steroids and cyclosporin [6]. It is important—but difficult—to know when cure
has been achieved in these patients since the withdrawal of immunosuppressants during antil-
eishmania treatment is commonly required, and there is a risk of relapse when immunosup-
pression is restored. In addition, in Leishmania-endemic areas, relatively high case numbers of
VL have been noticed among people treated with tumour necrosis factor (TNF) antagonists or
blockers of the TNF receptor for several months [7]. Very little is known, however, about the
relationship between leishmaniasis and pharmacological immunosuppression. Nor is the prev-
alence of asymptomatic Leishmania infection in this immunosuppressed population known.
A lymphoproliferative response to soluble Leishmania antigen (SLA), along with the pro-
duction of cytokines associated with the Th1 response, is a marker of recovery from VL and a
sign that immune memory against the parasite has been achieved [8]. Cytokine release assays
are also now beginning to be used to identify asymptomatic patients [9–12]. The present work
describes how these assays can be used to confirm the cure of VL in patients with autoimmune
disease, and to determine the prevalence of asymptomatic Leishmania infection in the popula-
tion receiving immunosuppressants. This method could be used better manage VL in patients
with autoimmune disease—in whom immunosuppression is normally halted during antipara-
site treatment—and to identify patients with autoimmune disease who have asymptomatic
Leishmania infection, who are at risk of developing VL because of their immunosuppressive




This study was approved by the Hospital de Fuenlabrada (APR 12–65 and APR14-64). All par-
ticipants gave their written, informed consent to be included.
Patients and blood samples
Blood samples were taken from 108 volunteers undergoing immunosuppressant treatment for
autoimmune conditions at the above hospital, all of whom were aged over 18 years. All were
residents of Fuenlabrada (Madrid, Spain), an area endemic for Leishmania infantum and
where the overall prevalence of infection is high. Of these 108 patients, 94 had no history of
leishmaniasis (NH), and 14 were ostensibly cured of VL (CVL patients) according to WHO
criteria (i.e., no symptoms 6 months after completing pharmacological anti-Leishmania treat-
ment; blood samples for these patients were taken 6 months after treatment for VL ended).
Blood samples were also available for 5 of these latter 14 patients during the time when they
had active VL (AVL). All blood samples were subjected to specific humoral, cellular and
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molecular tests for Leishmania, and their cytokine profiles determined. Cellular tests were
always performed within 24 hours after sample reception.
The case definition of AVL was clinical manifestations compatible with the condition plus
at least one of the following [7]: (i) positive parasitological test (blood/bone marrow PCR);
and/or (ii) positive serological [rK39-ICT and ELISA/IFAT (enzyme-linked immunosorbent
assay/indirect immunofluorescent antibody test)] test plus clinical response to treatment.
Treatments administered
S1 and S2 Tables show the characteristics of, and treatments received by, the 94 NH patients
and the 14 patients ostensibly cured of VL, respectively.
Preparation of soluble Leishmania antigen
Soluble L. infantum antigen (SLA) was prepared from promastigote cultures in the stationary
phase (JPC strain, MCAN/ES/98/LLM-722), as previously described [13]. The parasites were
first washed with 1X phosphate-buffered saline (PBS) and centrifuged at 1000 g for 20 min at
4˚C. The supernatant was discarded and the pellet resuspended in lysis buffer (50 mM Tris/5
mM EDTA/HCl, pH 7). These samples were subjected to three cycles of freezing/thawing, and
then sonicated three times (40 W for 20 s). The parasite suspension was then centrifuged at
27,000 × g for 20 min. The supernatant was collected and centrifuged at 100,000 × g for 4 h,
divided into aliquots, and stored at -80˚C until use. The protein content was quantified follow-
ing the Bradford method, using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific).
Enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assay (ELISA) was used to detect antibodies in blood to SLA
[12]. Briefly, 96-well plates (NuncMaxisorp Immuno Plates, USA) were coated with 100 μl/
well of 10 μg/ml SLA and left overnight at 4˚C. The plates were then washed three times with
PBS, 0.1% Tween 20 (PBS-T), pH7.4, and blocked with 200 μl/well of PBS containing 0.1%
Tween 20 and 3% BSA for 1 h at 37˚C. After washing with PBS-T, diluted blood plasma (1/200
in PBS-T) was added (100 μl/well) and incubated for 2 h at 37˚C. The plates were then washed
with PBS-T and 100 μl/well of 1/5000-diluted HRP-conjugated anti-human Ig (Invitrogen,
USA) were added for 30 min at 37˚C. All plates were then developed with 100 μl/well of Sigma
Fast o-phenylene diamine dihydrochloride (OPD) tablets (Sigma, USA) for 20 min. The reac-
tion was stopped with 50 μl/well of 2NHCl, and absorbance measured at 492 nm.
Immunofluorescent antibody titres
Immunofluorescent antibody titre (IFAT) analyses of plasma samples were performed using
2 × 105 L. infantum promastigotes in PBS per well (MCAN/ES/98/LLM-722), as previously
described [12]. Patient plasma was assayed as two-fold serial dilutions (from 1/20 to 1/640) in
PBS to determine total IgG levels using fluorescein isothiocyanate-conjugated goat antihuman
IgG (Fluoline G) (BioMérieux, France) diluted 1/200. The threshold titre for positivity was set
at 1:80.
rK39-ICT serological test
The rK39-ICT test (Leti Laboratories, Spain) is a rapid, commercial, immunochromatographic
test for the quantitative detection of Leishmania antibodies in serum. Serum (25 μl) was added
to the test strips, along with the provided buffer solution, in 2 ml Eppendorf tubes. After 10
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min at room temperature, the strips were examined for the two bands (control and specific)
indicating a positive result.
DNA extraction and Leishmania nested PCR
DNA was extracted from 200 μl whole blood to which had been added 400 μl of NET10 (10
mM NaCl, 10 mM EDTA, 10 mM Tris HCl), 40 μl of SDS sample buffer (10%), and 2 μl of pro-
teinase K. Samples were incubated with agitation overnight at 56˚C. The DNA was isolated
using the phenol-chloroform method, precipitating in ethanol [14]. The total DNA was resus-
pended in 100 μl of sterile distilled water and quantified using a UV-V ND-100 spectropho-
tometer (NanoDrop Technology, USA). The extracted DNA was subjected to nested PCR (Ln-
PCR) using primer pairs that amplify the Leishmania small ribosomal subunit (SSUrRNA)
[15], employing a GenAmp PCR System 2700 thermocycler (Applied Biosystems, USA). The
first round of reactions (30 cycles, annealing temperature 60˚C) involved the use of primers
R221 and R332. The amplicons were diluted 1/40 in distilled water, and 10 μl of this dilution
used in the second round of reactions, which involved the use of primers R223 and R333 (30
cycles, annealing temperature 65˚C). The amplicons were then visualised in 1.5% agarose gels
in TAE buffer (Tris-acetate 0.04 mM, EDTA 1 μM, pH 8) using 0.02% GelRed staining (Bio-
tium, USA) under a MiniBis-proilluminator (DNR, Bio-imaging systems, Israel). Positive
results require amplicons of 358 bp be detected.
Culturing and stimulation of peripheral blood mononuclear cells
(lymphoproliferative or cell proliferation assay [CPA])
Blood samples (10 ml) were collected in heparinised vials from all subjects. Peripheral blood
mononuclear cells (PBMC) were separated out using a Ficoll-Hypaque gradient (Rafer, Spain),
resuspended in complete RPMI supplemented with 10% foetal bovine serum, and cultured (in
triplicate) at an initial concentration of 2x10^6 cells/ml in 96-well plates with either complete
RPMI (negative control) or SLA (10 μg/ml) [12]. All cultures were kept for 6 days at 37˚C in a
5% CO2 atmosphere. The lymphoproliferative response of each subject was then determined
by bromodeoxyuridine incorporation using the Cell Proliferation Kit (GE Healthcare Life Sci-
ences, UK), following the manufacturer’s instructions. Results were expressed in the form of a
stimulation index (SI, the absorbance of stimulated cells/unstimulated cells). The cut-off for a
positive lymphoproliferative response (stimulation index 2.5) was determined using a receiver
operating curve (ROC). Note that the culture supernatants were collected and stored at -20˚C
for later cytokine analysis (see below).
Stimulation of whole blood with SLA (whole blood assay [WBA])
Aliquots (500 μl) of whole blood were incubated in tubes with 10 μg/ml SLA or 5 μg/ml
PHA-M. A further tube with no SLA was used as a negative control. All tubes were incubated
at 37˚C for 24 h, as previously described [10,12]. They were then centrifuged at 2000 g for 10
min. The supernatants were then removed and kept at -20˚C for later cytokine analysis. Results
for each cytokine were expressed as the difference between the SLA-stimulated and control
plasma concentrations.
Cytokine release assays
IL-2, IP-10, IFN-γ, TNF-α and granzyme B were determined in 50 μl of plasma from SLA-
stimulated whole blood and the supernatants of SLA-stimulated PBMC (see above) using the
CBA Human Soluble Protein Flex Set Capture Bead Kit (Becton Dickinson Spain) according
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to the manufacturer’s instructions. The flow cytometry results obtained were analysed using
FCAP Array v.3.0.1 software. The cut-off for asymptomatic infection and cure for each cyto-
kine were determined using receiver operating curves (ROC).
Statistical analysis
The normality of distributions was checked using the Shapiro-Wilk test. Accordingly, the
Mann-Whitney U test was used to analyse differences between the different groups. Signifi-
cance was set at p<0.050. All calculations were made using GraphPad Prism v. 5 software.
Results
Immunological response and parasite load
Of the 108 patients examined, the 14 CVL patients all returned a negative Ln-PCR test and all
mounted positive serological responses. Three of the five patients for whom blood was avail-
able before cure, i.e., when they still had AVL, returned a positive Ln-PCR test and at least one
positive serological test (Table 1). The 94 NH patients returned negative serological and Ln-
PCR tests (Table 1).
Of the 94 NH subjects, 20 showed a positive CPA test under SLA challenge (p<0.0001);
these were classified as asymptomatic immune responders to Leishmania (NH-AIRL) (Fig 1).
The mean SI of these 20 subjects was 4.26 compared to 1.33 for the remaining 74 NH non-
responders. The prevalence of asymptomatic infection was therefore 21.27% (20/94). All of the
CVL patients returned a positive response (Fig 1), and showed a significantly different SI to
Table 1. Mean age of subjects and percentages with positive Ln-PCR, IFAT, rk39-ICT and ELISA tests.
Age in years (mean ± SD) % Ln-PCR positive % IFAT positive % rk39-ICT positive % ELISA positive
NH (n = 94) 48 ± 13 0 (0/94) 0 (0/94) 0 (0/94) 0 (0/94)
CVL (n = 14) 59 ± 13 0 (0/14) 64 (9/14) 71 (10/14) 71 (10/14)
AVL (n = 5) 57 ± 12 60 (3/5) 100 (5/5) 80 (4/5) 100 (5/5)
https://doi.org/10.1371/journal.pntd.0009662.t001
Fig 1. Lymphoproliferative response (CPA test) results following stimulation of their PBMC with SLA. Patients
with no history of leishmaniasis who did not respond (NH n = 74), asymptomatic immune responders to Leishmania
(NH-AIRL n = 20), patients cured of VL (CVL n = 14), and the five AVL patients (i.e., samples from 5 of the CVL
patients during early disease). �p<0.050, �� p<0.010, ��� p<0.001, ���� p<0.0001.
https://doi.org/10.1371/journal.pntd.0009662.g001
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the NH patients (p<0.0001). The five AVL patients all returned a negative result, with signifi-
cant differences in SI with respect to the above NH-AIRL individuals and the CVL patients
(p<0.010 and p<0.001 respectively).
Following stimulation of the PBMC of all subjects with PHA-M, no significant difference
was seen among the NH [SI 6.422 (4.79–9.10)], NH-AIRL [SI 4.306 (3.55–8.91)], CVL [SI 9.93
(3.70–8.72)], and AVL [SI 3.739 (2.68–12.23)] groups in terms of response; they were well
capable of responding to PHA-M.
Cytokine profiles of supernatants from SLA-stimulated PBMC cultures
For practical and economic reasons, a random sample of 44 NH patients (hereinafter NC [nor-
mal control]) was selected from the original 74 NH non-responders, and their data used in the
analysis of the cytokine profile results.
Compared to the NC patients, the NH-AIRL patients showed significantly higher values for
IFN-γ (p<0.001), TNF-α (p<0.001), granzyme B (p<0.0005) and IP-10 (p<0.010) (Fig 2). The
CVL patients had the same cytokine profile as the NH-AIRL patients, with no significant dif-
ferences between these groups for any of the measured variables.
Fig 2. Production of a) IFN-γ, b) TNF-α, c) granzyme B and d) IP-10 in supernatants of PBMC cultures stimulated with SLA. NC normal controls,
NH-AIRL asymptomatic immune responders to Leishmania, CVL patients cured of leishmaniasis, and AVL patients with active VL. �p<0.050, ��p<0.010,
��� p<0.001.
https://doi.org/10.1371/journal.pntd.0009662.g002
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Compared to the CVL patients, the AVL patients returned significantly lower values for all
four cytokines measured: IFN-γ (p<0.010), TNF-α (p<0.010), granzyme B (p< 0.010) and IP-
10 (p<0.050) (Fig 2).
Quantification of cytokines in plasma from SLA-stimulated whole blood
For the same practical and economic reasons, the random sample of 44 NC patients was used
in the cytokine analysis of plasma from SLA-stimulated whole blood. Compared to the plasma
from the NC patients, that of NH-AIRL patients contained more IFN-γ (p<0.001), TNF-α
(p<0.050), granzyme B (p<0.001), IP-10 (p<0.001) and IL-2 (p<0.001) (Fig 3). The CVL
patients showed the same pattern. Compared to the CVL patients, the AVL patients showed
lower values for IFN-γ (p<0.050), IP-10 and IL-2 (p<0.010) (Fig 3).
Cytokine profiles from PHA-stimulated samples
Non-specific stimulation of the PBMC with PHA-M led to an efficient Th1 response that was
similar in the NC, AIRL and CVL subjects; not for AVL, as expected (S3 Table). Granzyme B
production in PHA-stimulated PBMC cultures was however, significantly higher in the CVL
subjects than in the NH subjects (p<0.050). In addition, IP-10 and IL-2 production in PHA-
stimulated blood were significantly higher in the NH-AIRL subjects than in the CVL subjects
(p<0.050).
Identification of cured status and asymptomatic infection
The optimal cytokine cut-off values indicating cured status and asymptomatic infection were
determined by means of ROC analyses (S4 and S5 Tables). Table 2 shows the proportion of
patients with cytokine levels above their respective cut-off values.
Fig 3. a) IFN-γ, b) TNF-α, c) granzyme B, d) IP-10 and e) IL-2 in whole blood stimulated with SLA. NC normal controls, NH-AIRL asymptomatic
immune responders to Leishmania, CVL patients cured of leishmaniasis, and AVL patients with active VL. �p<0.050, ��p<0.010, ��� p<0.001.
https://doi.org/10.1371/journal.pntd.0009662.g003
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The NH-AIRL patients showed the ability to mount a specific Th1 response against Leish-
mania. After the stimulation of their PBMC, IFN-γ was produced above the cut-off, identifying
100% of this population. In plasma from SLA-stimulated whole blood, the production of IP-10
identified 90% of the patients with asymptomatic infection, but as described in immunocom-
petent subjects [10], IL-2 production identified 100% of this population. Of note, TNF-α pro-
duction may be influenced by the presence of anti-TNF treatments in the blood of some
patients (not critical in washed PBMC).
Discussion
The present work shows that cytokine assays can be used to detect asymptomatic Leishmania
infection in patients receiving immunosuppressant treatment for autoimmune conditions,
and to detect cure in those who require treatment for VL. In an earlier study, our group
showed that cytokine release assays can be used to determine cured status in patients who have
undergone solid organ transplantation [12]. In a further study in patients coinfected with
VIH/Leishmania, we showed the usefulness of the specific lymphoproliferative response to
SLA as a marker of cure in these patients, and as an indicator of the possibility of withdrawing
secondary prophylaxis [10].
In the present work, the CVL patients showed a specific cellular response and the strong
production of Th1-type cytokines. It remains unknown, however, how long these patients
maintain the immunological memory developed, or how this might be related to relapse. New
studies over longer periods will be needed to determine this. Certainly, these patients produced
IFN-γ, granzyme B and IP-10 at levels allowing them to be biomarkers of cure. These cytokines
should therefore be monitored as part of these patients’ management.
Molecular and serological techniques are very useful to diagnose AVL in autoimmune
patients, mainly ELISA /IFAT and PCR in bone marrow [16]. As the present results show, they
have certain limitations in determining VL cure. Although Ln-PCR did detect the parasites
during active VL [16], the number present in the blood declines rapidly to undetectable levels
after the first treatment dose [16]. This does not, however, indicate a cure to have been
achieved; some parasites may remain in the bone marrow. In previous work [17], the serologi-
cal tests used (the same as in the present study) were clearly less sensitive as a diagnostic tool in
patients coinfected with HIV/Leishmania since >40% made no antibodies. In contrast, in
patients immunosuppressed due to their having undergone solid organ transplantation, its
sensitivity was found to be about 93% [18]. It has also demonstrated to be a sensitive tool for
use in patients receiving anti-TNF treatment [16,19]. However, in the present patients, the
serological tests continued to return positive results after cure, rendering them unsuitable for
determining when cure is actually achieved.
Table 2. Proportion of patients that produced cytokine levels above the calculated optimal cut-off values after SLA-stimulation of a whole blood sample. NH-AIRL
asymptomatic immune responders to Leishmania, CVL patients cured of leishmaniasis.
Supernatants of SLA-stimulated PBMC cultures Plasma from SLA-stimulated whole blood
Analytes NH-AIRL CVL Analytes NH-AIRL CVL
N (%) N (%) N (%) N (%)
IFN-γ 20/20 (100) 13/14 (92) IFN-γ 15/20 (75) 10/11 (90)
TNF-α 17/20 (85) 9/14 (64) TNF-α 9/20 (45) 7/11 (63)
Granzyme B 18/20 (90) 13/14 (92) Granzyme B 14/20 (70) 8/11 (72)
IP-10 15/20 (75) 10/14 (71) IP-10 18/20 (90) 10/11 (90)
IL-2 0/20 (0) 0/14 (0) IL-2 20/20 (100) 9/11 (81)
https://doi.org/10.1371/journal.pntd.0009662.t002
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An asymptomatic person is usually regarded as someone from an endemic area who shows
an immune response (either antibodies or a specific cellular response) against Leishmania, or
who has parasites—or parasite DNA—in the blood [20–22]). Molecular methods such as PCR
have been used less often to identify asymptomatic infection due to low parasitemia [23]. Sero-
logical markers are often measured but they can revert to negative within 4 months [24]. How-
ever, cell immunity usually remains positive for several years, sometimes even throughout an
individual’s life [25], and this is the main reason to use tests that detect the cell-mediated
immune response when screening for asymptomatic subjects in areas with endemic leishmani-
asis. In fact, a cross-sectional survey of the immunocompetent population living in the same
area (Fuenlabrada, Madrid, Spain) recently showed a high prevalence of asymptomatic sub-
jects measured by WBA and IL-2 detection (20.7%) compared to the low levels detected by
serological techniques (1.1%) [26].
By using these assays, the present results also show that some 21.27% of the NH patients
had been in contact with the parasite. Supernatants from SLA-stimulated PBMC cultures
(from CPA tests) can be used to look for IFN-γ, while SLA-stimulated plasma (from WBA
tests) can be used to look for IP-10 and IL-2, all of which are biomarkers of the asymptomatic
condition. However, preparing the latter for cytokine levels to be determined is much easier;
indeed, WBA tests hold much promise in the point-of-care setting. Immunosuppressed but
asymptomatic immune responders to Leishmania should be monitored to help prevent the
development of VL and to treat it early if it does appear. This need is further to that outlined in
a study of HIV+ and transplanted patients from the same area, among whom similar asymp-
tomatic individuals were detected [10,12].
The present work is the first to show that the elevated production of certain cytokines fol-
lowing the SLA-stimulation of whole blood can be used to identify asymptomatic Leishmania
infection in immunosuppressed patients, and to confirm cure from VL in those who developed
this disease. Earlier studies in immunocompetent subjects showed the importance of IFN-γ,
IL-2 and IP-10 in the identification of asymptomatic immune responders to Leishmania
(NH-AIRL-type patients) [9,27]. These same molecules have also been shown useful in the
detection of asymptomatic Leishmania infection in transplanted patients and patients coin-
fected with HIV [11,12].
Although some unspecific reactions have been described for SLA antigen in patients with
tuberculosis, brucellosis, typhoid fever, malaria or trypanosomiasis, none of our patients had
had previously any of these infections. In addition, our previous works with solid organ trans-
plant patients reinforce the specificity of the antigen in patients under immunosuppressive
treatments. Although current literature has not shown unspecific cytokine release for SLA
antigen in blood from autoimmune patients, molecular mimicry exists between antigens from
Leishmania sp. and patients with systemic lupus erythematosus [28], consequently new studies
are need in order to clarify this complex issue.
The main limitation of this study is the size of the cohorts of immunosuppressed patients
because the heterogeneity of the treatments and patients’ conditions could affect the obtained
results. In addition, other epidemiological areas should be also studied.
In conclusion, the present results show that cytokine release assays can be used to confirm
the cure of VL in patients with autoimmune disease, in whom immunosuppressive treatment
is usually suspended; confirmation of a cure would allow immunosuppression to be re-estab-
lished at the earliest opportunity. These assays can also be used to identify patients with auto-
immune disease who have asymptomatic Leishmania infection, and who are therefore at risk
of developing VL. Such knowledge would also be useful in efforts to control the spread of
Leishmania.
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